Advances in treatment for neurotrophic keratopathy

Current Opinion in Ophthalmology

Volumn 20, Issue 4, 2009, Pages 276-281

  Nishida, Teruo ^a   Yanai, Ryoji ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Corneal epithelium; Corneal innervation; Insulin like growth factor 1; Persistent epithelial erosions; Substance P

Indexed keywords

EYE DROPS; FIBRONECTIN; NERVE GROWTH FACTOR; SOMATOMEDIN C; SUBSTANCE P;

CLINICAL FEATURE; CORNEA EPITHELIUM; CORNEA INJURY; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; INNERVATION; KERATOPATHY; NEUROTROPHIC KERATOPATHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SERUM; STIMULUS RESPONSE; TRIGEMINAL NERVE; UMBILICAL CORD BLOOD; WOUND HEALING;

CORNEAL DISEASES; EPITHELIUM, CORNEAL; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEUROTRANSMITTER AGENTS; OPHTHALMIC SOLUTIONS; SUBSTANCE P; TRIGEMINAL NERVE; WOUND HEALING;

EID: 67651040841     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32832b758f     Document Type: Review

References (66)

1. Magendie PA. On the influence of the fifth pair of nerves on the nutrition and functions of the eye [in French]. J Physiol (Paris) 1824; 4:176-177.
2. Rose W. Surgical treatment of trigeminal neuralgia. Lancet 1892; 1:295-302.
3. Lambiase A, Rama P, Aloe L, et al. Management of neurotrophic keratopathy. Curr Opin Ophthalmol 1999; 10:270-276.
4. Davis EA, Dohlman CH. Neurotrophic keratitis. Int Ophthalmol Clin 2001; 41:1-11.
5. Pushker N, Dada T, Vajpayee RB, et al. Neurotrophic keratopathy. CLAO J 2001; 27:100-107.
6. Bonini S, Rama P, Olzi D, et al. Neurotrophic keratitis. Eye 2003; 17:989-995.
7. Goins KM. New insights into the diagnosis and treatment of neurotrophic keratopathy. Ocul Surf 2005; 3:96-110. (Pubitemid 40775111)
8. Nishida T. Neurotrophic mediators and corneal wound healing. Ocul Surf 2005; 3:194-202. (Pubitemid 41645655)
9. Tervo K, Tervo T, Eranko L, et al. Substance P immunoreactive nerves in the rodent cornea. Neurosci Lett 1981; 25:95-97. (Pubitemid 11030830)
10. Shimizu Y. Localization of neuropeptides in the cornea and uvea of the rat: an immunohistochemical study. Cell Mol Biol 1982; 28:103-110. (Pubitemid 12084694)
11. Shimizu Y, Kuwayama Y, Fukuda M, et al. Localization of substance P-like immunoreactivity in the anterior eye segment of squirrels: an immunohistochemical analysis. Invest Ophthalmol Vis Sci 1982; 22:259-263.
12. Tervo K, Tervo T, Eranko L, et al. Substance P-immunoreactive nerves in the human cornea and iris. Invest Ophthalmol Vis Sci 1982; 23:671-674. (Pubitemid 13236106)
13. Mishima S. The effects of the denervation and the stimulation of the sympathetic and the trigeminal nerve on the mitotic rate of the corneal epithelium in the rabbit. Jpn J Ophthalmol 1957; 1:65-73.
14. Cavanagh HD, Colley AM. The molecular basis of neurotrophic keratitis. Acta Ophthalmol Suppl 1989; 192:115-134.
15. Suda T, Nishida T, Ohashi Y, et al. Fibronectin appears at the site of corneal stromal wound in rabbits. Curr Eye Res 1981; 1:553-556.
16. Nishida T, Nakagawa S, Ohashi Y, et al. Fibronectin in corneal wound healing: appearance in cultured rabbit cornea. Jpn J Ophthalmol 1982; 26:410-415. (Pubitemid 13180729)
17. Nishida T, Nakagawa S, Awata T, et al. Fibronectin promotes epithelial migration of cultured rabbit cornea in situ. J Cell Biol 1983; 97:1653-1657. (Pubitemid 14230230)
18. Nishida T, Nakagawa S, Nishibayashi C, et al. Fibronectin enhancement of corneal epithelial wound healing of rabbits in vivo. Arch Ophthalmol 1984; 102:455-456. (Pubitemid 14197302)
19. Nishida T, Ohashi Y, Awata T, et al. Fibronectin. A new therapy for corneal trophic ulcer. Arch Ophthalmol 1983; 101:1046-1048.
20. Nishida T, Nakagawa S,Manabe R. Clinical evaluation of fibronectin eyedrops on epithelial disorders after herpetic keratitis. Ophthalmology 1985; 92:213-216. (Pubitemid 15137762)
21. von Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol (Lond) 1931; 72:74-87.
22. Datar P, Srivastava S, Coutinho E, et al. Substance P: structure, function, and therapeutics. Curr Topics Med Chem 2004; 4:75-103.
23. Chang MM, Leeman SE, Niall HD. Amino-acid sequence of substance P. Nat New Biol 1971; 232:86-87.
24. Pennefather JN, Lecci A, Candenas ML, et al. Tachykinins and tachykinin receptors: a growing family. Life Sci 2004; 74:1445-1463. (Pubitemid 38077208)
25. Nishida T, Nakamura M, Ofuji K, et al. Synergistic effects of substance P with insulin-like growth factor-1 on epithelial migration of the cornea. J Cell Physiol 1996; 169:159-166. (Pubitemid 26342525)
26. Nakamura M, Ofuji K, Chikama T, et al. Combined effects of substance P and insulin-like growth factor-1 on corneal epithelial wound closure of rabbit in vivo. Curr Eye Res 1997; 16:275-278. (Pubitemid 27129973)
27. Nakamura M, Chikama T, Nishida T. Synergistic effect with Phe-Gly-Leu-Met- NH2 of the C-terminal of substance P and insulin-like growth factor-1 on epithelial wound healing of rabbit cornea. Br J Pharmacol 1999; 127:489-497. (Pubitemid 29245688)
28. Nakamura M, Chikama TI, Nishida T. Characterization of insulin-like growth factor-1 receptors in rabbit corneal epithelial cells. Exp Eye Res 2000; 70: 199-204. (Pubitemid 30670364)
29. Yamada N, Yanai R, Nakamura M, et al. Role of the C domain of IGFs in synergistic promotion, with a substance P-derived peptide, of rabbit corneal epithelial wound healing. Invest Ophthalmol Vis Sci 2004; 45:1125-1131. (Pubitemid 38869017)
30. Yamada N, Yanai R, Kawamoto K, et al. Promotion of corneal epithelial wound healing by a tetrapeptide (SSSR) derived from IGF-1. Invest Ophthalmol Vis Sci 2006; 47:3286-3292. (Pubitemid 351639688)
31. Nakamura M, Ofuji K, Chikama T, et al. The NK1 receptor and its participation in the synergistic enhancement of corneal epithelial migration by substance P and insulin-like growth factor-1. Br J Pharmacol 1997; 120:547-552. (Pubitemid 27089398)
32. Yamada N, Yanai R, Inui M, et al. Sensitizing effect of substance P on corneal epithelial migration induced by IGF-1, fibronectin, or interleukin-6. Invest Ophthalmol Vis Sci 2005; 46:833-839. (Pubitemid 41321018)
33. Nakamura M, Chikama T, Nishida T. Up-regulation of integrin a5 expression by combination of substance P and insulin-like growth factor-1 in rabbit corneal epithelial cells. Biochem Biophys Res Commun 1998; 246:777-782. (Pubitemid 28420934)
34. Chikama T, Nakamura M, Nishida T. Up-regulation of integrin a5 by a Cterminus four-amino-acid sequence of substance P (phenylalanine-glycineleucine- methionine-amide) synergistically with insulin-like growth factor-1 in SV-40 transformed human corneal epithelial cells. Biochem Biophys Res Commun 1999; 255:692-697. (Pubitemid 29294860)
35. Ofuji K, Nakamura M, Nishida T. Signaling regulation for synergistic effects of substance P and insulin-like growth factor-1 or epidermal growth factor on corneal epithelial migration. Jpn J Ophthalmol 2000; 44:1-8. (Pubitemid 30029127)
36. Nakamura M, Nagano T, Chikama T, et al. Up-regulation of phosphorylation of focal adhesion kinase and paxillin by combination of substance P and IGF-1 in SV-40 transformed human corneal epithelial cells. Biochem Biophys Res Commun 1998; 242:16-20. (Pubitemid 28412369)
37. Nakamura M, Chikama T, Nishida T. Participation of p38 MAP kinase, but not p44/42 MAP kinase, in stimulation of corneal epithelial migration by substance P and IGF-1. Curr Eye Res 2005; 30:825-834. (Pubitemid 43154700)
38. Nagano T, Nakamura M, Nakata K, et al. Effects of substance P and IGF-1 in corneal epithelial barrier function and wound healing in a rat model of neurotrophic keratopathy. Invest Ophthalmol Vis Sci 2003; 44:3810-3815. (Pubitemid 37047950)
39. Nakamura M, Kawahara M, Nakata K, et al. Restoration of corneal epithelial barrier function and wound healing by substance P and IGF-1 in rats with capsaicin-induced neurotrophic keratopathy. Invest Ophthalmol Vis Sci 2003; 44:2937-2940. (Pubitemid 36759755)
40. Chikama T, Wakuta M, Liu Y, et al. Deviated mechanism of wound healing in diabetic corneas. Cornea 2007; 26:S75-S81. (Pubitemid 47442767)
41. Sato N, Nakamura M, Chikama T, et al. Abnormal deposition of laminin and type IV collagen at corneal epithelial basement membrane during wound healing in diabetic rats. Jpn J Ophthalmol 1999; 43:343-347. (Pubitemid 29415727)
42. Morishige N, Chikama TI, Sassa Y, et al. Abnormal light scattering detected by confocal biomicroscopy at the corneal epithelial basement membrane of subjects with type II diabetes. Diabetologia 2001; 44:340-345. (Pubitemid 32234461)
43. Kaji Y, Usui T, Oshika T, et al. Advanced glycation end products in diabetic corneas. Invest Ophthalmol Vis Sci 2000; 41:362-368. (Pubitemid 30080435)
44. Azar DT, Spurr-Michaud SJ, Tisdale AS, et al. Decreased penetration of anchoring fibrils into the diabetic stroma: a morphometric analysis. Arch Ophthalmol 1989; 107:1520-1523.
45. Azar DT, Spurr-Michaud SJ, Tisdale AS, et al. Altered epithelial-basement membrane interactions in diabetic corneas. Arch Ophthalmol 1992; 110: 537-540.
46. Taylor HR, Kimsey RA. Corneal epithelial basement membrane changes in diabetes. Invest Ophthalmol Vis Sci 1981; 20:548-553. (Pubitemid 11007359)
47. Saito J, Enoki M, Hara M, et al. Correlation of corneal sensation, but not of basal or reflex tear secretion, with the stage of diabetic retinopathy. Cornea 2003; 22:15-18. (Pubitemid 36076675)
48. Brown SM, Lamberts DW, Reid TW, et al. Neurotrophic and anhidrotic keratopathy treated with substance P and insulinlike growth factor 1. Arch Ophthalmol 1997; 115:926-927. (Pubitemid 127744594)
49. Chikama T, Fukuda K, Morishige N, et al. Treatment of neurotrophic keratopathy with substance-P-derived peptide (FGLM) and insulin-like growth factor I. Lancet 1998; 351:1783-1784. (Pubitemid 28269191)
50. Morishige N, Komatsubara T, Chikama T, et al. Direct observation of corneal nerve fibres in neurotrophic keratopathy by confocal biomicroscopy. Lancet 1999; 354:1613-1614. (Pubitemid 29515959)
51. Nishida T, Chikama T, Morishige N, et al. Persistent epithelial defects due to neurotrophic keratopathy treated with a substance P-derived peptide and insulin-like growth factor 1. Jpn J Ophthalmol 2007; 51:442-447.
52. Yamada N, Matsuda R, Morishige N, et al. Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy. Br J Ophthalmol 2008; 92: 896-900. This study describes the results of an open clinical study examining the effects of eyedrops containing the substance P-derived peptide FGLM-amide and the IGF-1- derived peptide SSSR in 26 eyes with neurotrophic keratopathy.
53. Kimura K, Hattori A, Usui Y, et al. Stimulation of corneal epithelial migration by a synthetic peptide (PHSRN) corresponding to the second cell-binding site of fibronectin. Invest Ophthalmol Vis Sci 2007; 48:1110-1118. (Pubitemid 351261404)
54. Lambiase A, Bonini S, Bonini S, et al. Increased plasma levels of nerve growth factor in vernal keratoconjunctivitis and relationship to conjunctival mast cells. Invest Ophthalmol Vis Sci 1995; 36:2127-2132.
55. Lambiase A, Bonini S, Micera A, et al. Expression of nerve growth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases. Invest Ophthalmol Vis Sci 1998; 39:1272-1275. (Pubitemid 28247365)
56. Lambiase A, Manni L, Bonini S, et al. Nerve growth factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and human corneas. Invest Ophthalmol Vis Sci 2000; 41:1063-1069. (Pubitemid 30187542)
57. Lambiase A, Rama P, Bonini S, et al. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med 1998; 338:1174-1180. (Pubitemid 28180745)
58. Bonini S, Lambiase A, Rama P, et al. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology 2000; 107:1347-1351. (discussion: 1351-1352).
59. Cellini M, Bendo E, Bravetti GO, et al. The use of nerve growth factor in surgical wound healing of the cornea. Ophthalmic Res 2006; 38:177-181. (Pubitemid 44213976)
60. Tan MH, Bryars J, Moore J. Use of nerve growth factor to treat congenital neurotrophic corneal ulceration. Cornea 2006; 25:352-355.
61. Lambiase A, Coassin M, Sposato V, et al. NGF topical application in patients with corneal ulcer does not generate circulating NGF antibodies. Pharmacol Res 2007; 56:65-69. (Pubitemid 46994753)
62. Aloe L, Tirassa P, Lambiase A. The topical application of nerve growth factor as a pharmacological tool for human corneal and skin ulcers. Pharmacol Res 2008; 57:253-258. This review article describes laboratory and clinical studies of NGF treatment for nonhealing corneal ulcer associated with neurotrophic keratopathy.
63. Poon AC, Geerling G, Dart JK, et al. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol 2001; 85:1188-1197. (Pubitemid 32929543)
64. Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology 2004; 111:1115-1120. (Pubitemid 38736990)
65. Vajpayee RB, Mukerji N, Tandon R, et al. Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects. Br J Ophthalmol 2003; 87:1312-1316. (Pubitemid 37452549)
66. Yoon KC, You IC, Im SK, et al. Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis. Ophthalmology 2007; 114:1637-1642.